Physician profile
Mark A Simon
NPI 1083654081
$5,728.74
in general payments reported to CMS, 2019-2025
26 companies · $779 in 2025
The $779 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $480 · 2021: $898 · 2022: $847 · 2023: $805 · 2024: $673 · 2025: $779.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,066.03 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $671.25 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $651.86 | 2019-2024 | Xarelto |
| Amgen INC. | $619.48 | 2019-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $412.09 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $369.54 | 2019-2024 | Camzyos, Eliquis |
| Abbott Laboratories | $340.93 | 2019-2025 | Aveir, Jot Dx |
| Bayer Healthcare Pharmaceuticals INC. | $239.70 | 2021-2025 | |
| Pfizer INC. | $210.83 | 2019-2024 | |
| Kestra Medical Technology Services, INC. | $173.82 | 2023-2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $156.23 | 2021-2025 | Nexletol |
| Alnylam Pharmaceuticals INC. | $137.69 | 2021-2025 | Onpattro |
| Amarin Pharma, INC. | $106.73 | 2019-2021 | |
| Kiniksa Pharmaceuticals International, Plc | $100.70 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals Lp | $95.25 | 2019-2024 | Farxiga, Lynparza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $66.23 | 2023-2025 | Barostim Neo System |
| Heartflow, INC. | $58.21 | 2024-2025 | |
| Boston Scientific Corporation | $53.29 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $41.00 | 2025 | Gemtesa |
| Novo Nordisk INC | $30.89 | 2025 | Wegovy |
| Acutus Medical, INC. | $26.49 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.73 | 2020-2023 | Lifevest |
| Edwards Lifesciences Corporation | $22.70 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Inari Medical, INC. | $19.16 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Medtronic, INC. | $18.42 | 2021 | |
| Scpharmaceuticals INC. | $14.49 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Simon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.